Abstract

Background Soluble lectin-like oxidized low-density lipoprotein receptor-1 (sLOX-1) may be a potential biomarker of coronary artery disease (CAD) and stroke. Objective We aimed to investigate the association and prognostic value of elevated sLOX-1 concentrations with regard to long-term major adverse cardiovascular and cerebrovascular events (MACCEs) in patients with CAD undergoing primary percutaneous coronary intervention (PCI). Methods A total of 1011 patients were enrolled. Serum sLOX-1 concentrations were detected by the enzyme-linked immunosorbent assay (ELISA). Patients were followed for 2 years. Multivariate Cox regression and Kaplan-Meier survival curve were explored to assess the association between sLOX-1 and MACCEs. A receiver operating characteristic (ROC) curve was used to evaluate the diagnostic efficacy of sLOX-1. Results Two-year MACCEs were associated with serum sLOX-1 concentrations (HR 1.278, 95% CI 1.019-1.604, P = 0.034), left main disease (HR 2.938, 95% CI 1.246-6.925, P = 0.014), small-caliber stents used (HR 2.207, 95% CI 1.189-4.095, P = 0.012), and total stent length (HR 1.057, 95% CI 1.005-1.112, P = 0.030). Serum sLOX-1 concentration ≥ 1.10 ng/ml had maximum sensitivity and specificity in predicting the occurrence of 2-year MACCEs (P < 0.001). Patients with higher serum sLOX-1 concentrations showed a significantly higher incidence of MACCEs in the Kaplan-Meier curve (P < 0.001). The combination of any of the risk factors identified in multiple Cox regression was associated with a stepwise increase in MACCE rate (P < 0.001). Conclusions High baseline serum sLOX-1 concentration predicts 2-year MACCEs and shows an additional prognostic value to conventional risk factors in patients after primary PCI. sLOX-1 determination might play a complementary role in the risk stratification of patients with CAD treated with PCI.

Highlights

  • Cardiovascular diseases remain the leading cause of mortality and disability worldwide, with coronary artery disease (CAD) accounting for the greatest proportion [1]

  • The results revealed that 2-year major adverse cardiovascular and cerebrovascular events (MACCEs) after percutaneous coronary intervention (PCI) were associated with serum Soluble lectin-like oxidized low-density lipoprotein receptor-1 (sLOX-1) concentrations (HR 1.278, 95% CI 1.019-1.604, P = 0:034), left main disease (HR 2.938, 95% CI 1.246-6.925, P = 0:014), small-caliber stents used (HR 2.207, 95% CI 1.189-4.095, P = 0:012), and total stent length (HR 1.057, 95% CI 1.005-1.112, P = 0:030)

  • Total stent length Combined risk factors Reference line. In this multicenter cohort study, we evaluated the association between baseline sLOX-1 concentration and long-term cardiovascular outcomes in patients undergoing PCI

Read more

Summary

Introduction

Cardiovascular diseases remain the leading cause of mortality and disability worldwide, with coronary artery disease (CAD) accounting for the greatest proportion [1]. The use of percutaneous coronary intervention (PCI) and new drug therapies has considerably improved the prognosis, patients with CAD remain at increased risk of major adverse cardiovascular and cerebrovascular events (MACCEs). We aimed to investigate the association and prognostic value of elevated sLOX-1 concentrations with regard to long-term major adverse cardiovascular and cerebrovascular events (MACCEs) in patients with CAD undergoing primary percutaneous coronary intervention (PCI). Two-year MACCEs were associated with serum sLOX-1 concentrations (HR 1.278, 95% CI 1.019-1.604, P = 0:034), left main disease (HR 2.938, 95% CI 1.246-6.925, P = 0:014), small-caliber stents used (HR 2.207, 95% CI 1.189-4.095, P = 0:012), and total stent length (HR 1.057, 95% CI 1.005-1.112, P = 0:030). High baseline serum sLOX-1 concentration predicts 2-year MACCEs and shows an additional prognostic value to conventional risk factors in patients after primary PCI. High baseline serum sLOX-1 concentration predicts 2-year MACCEs and shows an additional prognostic value to conventional risk factors in patients after primary PCI. sLOX-1 determination might play a complementary role in the risk stratification of patients with CAD treated with PCI

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call